Psyence Biomedical Ltd. (PBM)

Psyence Biomedical Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Selling, General & Admin	3.32	1.8	1.63	1.72
Research & Development	0.34	0.95	1.61	0.14
Operating Expenses	3.66	2.75	3.23	1.86
Operating Income	-3.66	-2.75	-3.23	-1.86
Interest Expense	-0.01	-0.05	-	-
Interest & Investment Income	0.1	0	0	-
Currency Exchange Gain (Loss)	-0.01	-0	0.03	-0
Other Non Operating Income (Expenses)	0.51	0.57	-	-
EBT Excluding Unusual Items	-3.07	-2.23	-3.21	-1.86
Gain (Loss) on Sale of Investments	0.02	-	-	-
Other Unusual Items	4.06	-48.93	-	-
Pretax Income	1.01	-51.16	-3.21	-1.86
Net Income	1.01	-51.16	-3.21	-1.86
Net Income to Common	1.01	-51.16	-3.21	-1.86
Shares Outstanding (Basic)	0	0	-	-
Shares Outstanding (Diluted)	0	0	-	-
Shares Change (YoY)	122.15%	-	-	-
EPS (Basic)	41.77	-4692.20	-	-
EPS (Diluted)	41.77	-4692.20	-	-
Free Cash Flow	-3.74	-2.95	-1.59	-1.4
Free Cash Flow Per Share	-154.58	-270.67	-	-
EBITDA	-3.66	-2.75	-	-
D&A For EBITDA	0	0	-	-
EBIT	-3.66	-2.75	-3.23	-1.86

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q